Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo‐controlled phase I/II trial of CAT‐192

Objective To evaluate CAT‐192, a recombinant human antibody that neutralizes transforming growth factor β1 (TGFβ1), in the treatment of early‐stage diffuse cutaneous systemic sclerosis (dcSSc). Methods Patients with SSc duration of

Saved in:
Bibliographic Details
Published in:Arthritis and rheumatism 2007-01, Vol.56 (1), p.323-333
Main Authors: Denton, Christopher P., Merkel, Peter A., Furst, Daniel E., Khanna, Dinesh, Emery, Paul, Hsu, Vivien M., Silliman, Nancy, Streisand, James, Powell, John, Åkesson, Anita, Coppock, John, Hoogen, Frank van den, Herrick, Ariane, Mayes, Maureen D., Veale, Douglas, Haas, Joanna, Ledbetter, Stephen, Korn, Joseph H., Black, Carol M., Seibold, James R.
Format: Article
Language:English
Subjects:
Biological and medical sciences
Medical sciences
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To evaluate CAT‐192, a recombinant human antibody that neutralizes transforming growth factor β1 (TGFβ1), in the treatment of early‐stage diffuse cutaneous systemic sclerosis (dcSSc). Methods Patients with SSc duration of
ISSN:0004-3591
1529-0131
DOI:10.1002/art.22289